Heather Fairfield, MS
Research Associate III
Research Interests: My background is in molecular biology and Mendelian genetics with a focus in hormonal regulation of both metabolic genes and oncogenes. I am interested in the use of high-throughput sequencing (exome, whole genome, and RNA-Seq) to identify spontaneous mutations, and have been involved in the implementation of these techniques in mice. I received my B.A. in Biology from the University of Vermont studying the mouse mammary tumor virus and a M.S. in Biology from Wake Forest University investigating the regulation of the leptin gene by steroid hormones. I am very interested in the relationship between adipocytes and multiple myeloma (MM) cells within the bone marrow (BM) niche, and what potential MM-nourishing signals may be released by these BM-adipocytes. I’m also interested in the genetic characterization of MM cells: both primary, potentially initiating mutations, and secondary events that may lead to distinctive gene expression signatures and disease progression.
Carolyne Falank, PhD
Research Interests: I obtained my B.S. in Marine Science at the University of Maine in Orono, Maine in 2005, my M.S. in Applied Medical Sciences from the University of Southern Maine in Portland, Maine in 2009 and my Ph.D. in Biochemistry and Molecular Biology from the University of Maine in Orono, Maine in 2015. During my graduate research, I studied the carcinogenic. I will be focusing my research on the design of nanoparticles that will be used to deliver therapeutic drugs that target bone disease and Multiple Myeloma. These nanoparticles will facilitate drug delivery that will be tested in both in vitro and in vivo models, with the hope that this will provide more efficient and effective delivery techniques to multiple myeloma patients while impeding tumor growth in the bone. In addition, I will help with other projects in the characterization and discovery of how cells in the bone marrow niche work in the progression of Multiple Myeloma. Learn more about Dr. Falank’s research.
Majdi Masarwi, PhD
Research Interests: I received my BS in Pharmacy from Petra University, Amman, Jordan and my PhD degree in Biomedical Sciences, at the Laboratory of Molecular Endocrinology and Diabetes, Sackler Faculty of Medicine, Tel Aviv University. During my PhD research I was committed to investigating factors that limit catch-up growth after a period of food restriction in rat models. I’m pleased to be part of Dr. Reagan’s lab. During my postdoctoral research, I’ll deeply investigate the role of the Wnt signaling inhibitor Sclerostin (SOST gene) in bone marrow adipogenesis, and explore if it plays a role in mediating bone destruction and fractures in multiple myeloma disease in-vitro and in-vivo models. In addition, I will be involved in other projects investigating the molecular mechanistic association between bone marrow adipocytes and multiple myeloma disease in Dr. Reagan’s lab.
Research Interests: As an intern in the Reagan lab, I was focused on inhibiting Multiple Myeloma (MM) from homing to the bone marrow via sialylation. MM can be shielded by the bone from various chemotherapy treatments, so if MM can be contained in the blood it may be easier to treat. After I graduated with my BS in Human Biology from University of Southern Maine in 2017, I have focused on several projects such as the effects bone marrow adipocytes have on MM and how this can trigger specific responses to drug treatments, and using carbon nanotubes as a form of delivery system in the body.
Research Interests: Originally from the Pittsburgh, PA area, Samantha moved to Maine to attend the University of New England. She graduated with a Bachelor of Science in Marine Biology with a minor in Art. Since graduation, she has gained experience with patient care and wound care treatments. Samantha is excited to be a part of the Reagan lab where she will be honing her skills in a laboratory setting. Samantha’s focus of research will be to investigate the correlation between Multiple Myeloma (MM) and bone marrow (BM) adipocytes and how BM adipocytes are effected in the presence of different drug therapies.
Katherine Bonawitz, BS
Research Associate I
Research Interests: I am a recent graduate of the University of Southern Maine with a B.S. in Biology. I enjoy cycling, hiking, volunteering, and hanging out with my dog, Mikey. Academically, my interests include developmental biology and medicine. I am excited to be a part of the Reagan lab as I begin the next steps in my education and I hope to contribute to a better understanding of multiple myeloma.
Research Interests: I am currently working toward earning my degree in Biology with a Human Concentration at the University of Southern Maine. My passions are science and art and I live locally here in Maine, as I have my whole life. I am thrilled to be a part of Dr Reagan’s research and look forward to contributing to the team as I pursue my education.
McDonald MM, Reagan MR, Youlten SE, Mohanty ST, Seckinger A, Terry RL, Pettitt JA, Simic MK, Cheng TL, Morse A, Le LMT, Abi-Hanna D, Kramer I, Falank C, Fairfield H, Ghobrial IM, Baldock PA, Little DG, Kneissel M, Vanderkerken K, Bassett JHD, Williams GR, Oyajobi BO, Hose D, Phan TG, Croucher PI. Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma. Blood. 2017; 129(26):3452-3464. PMID: 28515094.
Liu P, Ji Y, Yuen T, Rendina-Ruedy E, DeMambro VE, Dhawan S, Abu-Amer W, Izadmehr S, Zhou B, Shin AC, Latif R, Thangeswaran P, Gupta A, Li J, Shnayder V, Robinson ST, Yu YE, Zhang X, Yang F, Lu P, Zhou Y, Zhu LL, Oberlin DJ, Davies TF, Reagan MR, Brown A, Kumar TR, Epstein S, Iqbal J, Avadhani NG, New MI, Molina H, van Klinken JB, Guo EX, Buettner C, Haider S, Bian Z, Sun L, Rosen CJ, Zaidi M. Blocking FSH induces thermogenic adipose tissue and reduces body fat. Nature. 2017; 546(7656):107-112. PMID: 28538730.
Soley L, Falank C, Reagan MR. MicroRNA Transfer Between Bone Marrow Adipose and Multiple Myeloma Cells. Current osteoporosis reports. 2017; 15(3):162-170. PMID: 28432594.
Fairfield H, Rosen CJ, Reagan MR. Connecting Bone and Fat: The Potential Role for Sclerostin.Current molecular biology reports. 2017; 3(2):114-121. NIHMSID: NIHMS869329 PMID: 28580233 PMCID: PMC5448707.
Sacco A, Kawano Y, Moschetta M, Zavidij O, Huynh D, Reagan MR, Mishima Y, Manier S, Park J, Morgan E, Takagi S, Wong KK, Carrasco R, Ghobrial IM, Roccaro AM. A novel in vivo model for studying conditional dual loss of BLIMP-1 and p53 in B-cells, leading to tumor transformation. American journal of hematology. 2017; PMID: 28474779.
McDonald MM, Fairfield H, Falank C, Reagan MR. Adipose, Bone, and Myeloma: Contributions from the Microenvironment. Calcified tissue international. 2017; 100(5):433-448. NIHMSID: NIHMS858417. PMID: 27343063. PMCID: PMC5396178.
Fairfield H, Falank C, Harris E, Demambro V, McDonald M, Pettitt JA, Mohanty ST, Croucher P, Kramer I, Kneissel M, Rosen CJ, Reagan MR. The skeletal cell-derived molecule sclerostin drives bone marrow adipogenesis. Journal of cellular physiology. 2017; PMID: 28460416
Glavey SV, Naba A, Manier S, Clauser K, Tahri S, Park J, Reagan MR, Moschetta M, Mishima Y, Gambella M, Rocci A, Sacco A, O’Dwyer ME, Asara JM, Palumbo A, Roccaro AM, Hynes RO, Ghobrial IM. Proteomic characterization of human multiple myeloma bone marrow extracellular matrix. Leukemia. 2017; PMID: 28344315
Goldstein RH*, Reagan MR*, Anderson K, Kaplan DL, and Rosenblatt M. Human bone marrow-derived MSCs can home to orthotopic breast cancer tumors and can promote bone metastasis. *Co-first authorship. Cancer Res. 2010; 70(24):10044-50. PMCID: PMC3017423.
Reagan MR, Kaplan DL. Concise review: Mesenchymal stem cell tumor-homing: detection methods in disease model systems. Stem Cells. 2011; 29(6):920-7. PMID: 21557390.
Reagan MR, Seib P, Sage E, McMillin D, Janes S, Mitsiades C, Kaplan DL. Cell-Based Anti-Cancer Implant Systems: TRAIL-Mesenchymal Stem Cells and Silk Scaffolds. J Breast Cancer. 2012;15(3):273-82. PMCID: PMC3468780.
Reagan, MR and Ghobrial IM. Multiple Myeloma-Mesenchymal Stem Cells: Characterization, Origin, and Tumor-Promoting Effects. Clin Cancer Res. 2012; 18(2):342-9. PMCID: PMC3261316.
Roccaro A, Sacco A, Maiso P, Azab A, Tai Y, Reagan MR, Azab F, Flores L, Campigotto F, Weller E, Anderson KC, Scadden D, Ghobrial I. Bone marrow mesenchymal stromal cell-derived exosomes support multiple myeloma pathogenesis. J Clin Invest. 2013;123(4):1542-55. PMCID: PMC3613927.
Glavey SV, Manier S, Natoni A, Sacco A, Moschetta M, Reagan MR, Murillo LS, Sahin I, Wu P, Mishima Y, Zhang Y, Zhang W, Zhang Y, Morgan G, Joshi L, Roccaro AM, Ghobrial IM, O’Dwyer ME.. The Sialyltransferase ST3GAL6 Influences Homing and Survival in Multiple Myeloma. Blood. 2014; Epub Ahead of print. PMID: 25061176
Swami A* & Reagan MR*, Basto P, Mishima Y, Kamaly N, Glavey S, Zhang S, Moschetta M, Seevaratnam D; Zhang Y, Liu J, Memarzadeh T, Wu J, Manier S, Shi J, Bertrand N, Lu ZN, Nagano K, Baron R, Sacco A, Roccaro AM, Farokhzad OC, Ghobrial IM. Engineered Nanomedicine for Myeloma and Bone Microenvironment Targeting. PNAS. 2014;111(28):10287-92. *Co-first authorship. PMCID: PMC4104924.
Reagan MR, Mishima Y, Glavey S, Zhang Y, Manier S, Lu ZN, Memarzadeh M, Zhang Y, Sacco A, Aljawai Y, Tai Y-T, Ready JE, Shi J, Kaplan DL, Roccaro AM, Ghobrial IM. Investigating osteogenic differentiation in Multiple Myeloma using a novel 3D bone marrow niche model. Blood. 2014; 124(22):3250-9. PMCID: PMC4239334.
Roccaro AM, Sacco A, Purschke WG, Moschetta M, Buchner K, Maasch C, Zboralski D, Zöllner S, Vonhoff S, Mishima Y, Maiso P, Reagan MR, Lonardi S, Ungari M, Facchetti F, Eulberg D, Kruschinski A, Vater A, Rossi G, Klussmann S, Ghobrial IM. SDF-1 inhibition targets the bone marrow niche for cancer therapy. Cell Reports. 2014; 9(1):118-28. PMCID: PMC4194173
Reagan MR, Liaw L, Rosen CJ & Ghobrial IM. Dynamic Interplay between Bone and Multiple Myeloma: Emerging Roles of the Osteoblast. Bone. 2015;75:161-169. PMID: 25725265